AU2003212739B2 - Recombinant protein C variants - Google Patents

Recombinant protein C variants Download PDF

Info

Publication number
AU2003212739B2
AU2003212739B2 AU2003212739A AU2003212739A AU2003212739B2 AU 2003212739 B2 AU2003212739 B2 AU 2003212739B2 AU 2003212739 A AU2003212739 A AU 2003212739A AU 2003212739 A AU2003212739 A AU 2003212739A AU 2003212739 B2 AU2003212739 B2 AU 2003212739B2
Authority
AU
Australia
Prior art keywords
apc
protein
variant
domain
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003212739A
Other languages
English (en)
Other versions
AU2003212739A1 (en
Inventor
Bjorn Dahlback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAC Thrombosis and Coagulation AB
Original Assignee
TAC Thrombosis and Coagulation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAC Thrombosis and Coagulation AB filed Critical TAC Thrombosis and Coagulation AB
Publication of AU2003212739A1 publication Critical patent/AU2003212739A1/en
Application granted granted Critical
Publication of AU2003212739B2 publication Critical patent/AU2003212739B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003212739A 2002-03-01 2003-02-28 Recombinant protein C variants Ceased AU2003212739B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36018102P 2002-03-01 2002-03-01
US60/360,181 2002-03-01
US40104202P 2002-08-06 2002-08-06
US60/401,042 2002-08-06
PCT/SE2003/000331 WO2003073980A2 (en) 2002-03-01 2003-02-28 Recombinant protein c variants

Publications (2)

Publication Number Publication Date
AU2003212739A1 AU2003212739A1 (en) 2003-09-16
AU2003212739B2 true AU2003212739B2 (en) 2008-01-17

Family

ID=27791634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003212739A Ceased AU2003212739B2 (en) 2002-03-01 2003-02-28 Recombinant protein C variants

Country Status (6)

Country Link
US (1) US20050176083A1 (cg-RX-API-DMAC10.html)
EP (1) EP1483380A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005518801A (cg-RX-API-DMAC10.html)
AU (1) AU2003212739B2 (cg-RX-API-DMAC10.html)
CA (1) CA2477876A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003073980A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048646A1 (en) * 2006-10-18 2008-04-24 Socratech L.L.C. Use of human protein c with altered glycosylation and sialic acid content as a medicament
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044000A1 (en) * 1997-04-03 1998-10-08 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c and protein s variants
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044000A1 (en) * 1997-04-03 1998-10-08 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c and protein s variants
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
WO2003073980A2 (en) 2003-09-12
US20050176083A1 (en) 2005-08-11
EP1483380A2 (en) 2004-12-08
AU2003212739A1 (en) 2003-09-16
CA2477876A1 (en) 2003-09-12
WO2003073980A3 (en) 2003-11-27
JP2005518801A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
CA1339815C (en) Modified factor vii/viia
DK1891091T3 (en) Coagulation factor-X polypeptides with modified activation properties
EP1991255B1 (en) Coagulation factor x polypeptides with modified activation properties
WO2001059084A1 (en) Protein c derivatives
KR20140066793A (ko) 연장된 반감기를 갖는 변형된 응고 인자 ＶＩＩａ
KR20110114587A (ko) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
JP4855627B2 (ja) 医薬用途のためのトロンボモジュリン
AU2002235073B2 (en) Protein C variants
AU2002235073A1 (en) Protein C variants
AU741798B2 (en) Recombinant protein C and protein S variants
US5405946A (en) Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
US20050176083A1 (en) Recombinant protein c variants
WO2001057193A2 (en) Protein c derivatives
HUP0102444A2 (hu) Protein-C származékok
US6998122B1 (en) Protein C derivatives
Roddick Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired